<DOC>
	<DOCNO>NCT01040598</DOCNO>
	<brief_summary>Eosinophilic Esophagitis ( EoE ) condition characterize commonly vomit , nausea , epigastric pain , dysphagia , heartburn food impaction among gastrointestinal symptom along obstructive esophageal symptom pediatric adult population . The pathology disease postulate allergy mediate incidence disease see parallel increase incidence allergy asthma . Most current therapy EoE direct decrease esophageal allergic inflammation mirror treatment option allergic asthma . Swallowed corticosteroid elimination diet elemental diet show variable efficacy improve symptom . However , specific pathophysiologic mechanism EoE still largely unknown definitive treatment completely resolve symptom histological finding . Omalizumab recently develop anti-IgE antibody show decrease use inhale oral corticosteroid improve asthma relate symptom patient allergic asthma . In study , Eosinophilic esophagitis use disease model study mechanism action monoclonal Anti-IgE antibody vivo . The resolution symptom clinically , histological change ( improvement ) response treatment Xolair ( omalizumab ) patient suffer EoE determine . The primary objective open label , study determine mucosal marker predict responder Omalizumab ( Xolair ) .</brief_summary>
	<brief_title>Identifying Responders Xolair ( Omalizumab ) Using Eosinophilic Esophagitis Disease Model</brief_title>
	<detailed_description>This open label mechanistic study learn effect Omalizumab clinical symptom immunohistological finding establish case EoE . The dosage Omalizumab base patient 's body weight baseline IgE level . Omalizumab administer subcutaneously every 2 4 week total duration 12 week . At enrollment , subject EGD biopsy perform confirm diagnosis EoE histologic analysis special staining . Blood drawn baseline test monthly safety lab . At end 12 week period , repeat endoscopy perform biopsy take stain various mucosal marker like IgE , IL-13 , IL-5 Tryptase . The patient follow response therapy regard resolution symptom improvement histology finding biopsy .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Inclusion criterion Established diagnosis eosinophilic esophagitis , determine eosinophil &gt; 15/high power field distal esophagus and/or microabscesses . Patients therapy either food avoidance swallow steroid , change food avoidance steroid dose therapy . One active symptom disease ( epigastric pain , vomiting , nausea , dysphagia heartburn ) least 2 day week . Failed response proton pump inhibitor negative ph probe test Negative impedance study . Males females age 1276 year . Exclusion criterion Patients gastrointestinal reflux disease . Eosinophilic disease stomach duodenum . Peripheral eosinophil count &gt; 1500 ( hyper eosinophilic syndrome ) . Women childbearing potential use two form contraception method ( ) include limited condom , diaphragm , oral contraceptive pill , hormonal method , intrauterine device tubal ligation vasectomy , well woman breastfeed Known sensitivity study drug ( ) class study drug ( ) . Patients severe medical condition ( ) view investigator prohibit participation study ( specify require ) . Use investigational agent last 30 day . Use systemic inhale steroid within past 1 month . History malignancy . Require chronic immunosuppressive therapy include cyclosporine , methotrexate , etc . Have treat Xolair within 12 month prior screen . Patients eosinophilic esophagitis remission swallow steroid . Patients asthma take inhaled steroid . Serum IgE level &lt; 30 IU/l &gt; 700 IU/l</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Eosinophilic Esophagitis</keyword>
	<keyword>Xolair</keyword>
	<keyword>Omalizumab</keyword>
	<keyword>Esophagitis</keyword>
	<keyword>Eosinophils</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>